Additionally, patients with diseases related to abnormal cell differentiation, such as diabetes mellitus that is caused by abnormal β-cells with ectopic expression of SOX9 and concomitant activation of Wnt signalling (Puri et al., 2013), may benefit from in vivo medication delivery targeting aberrant SOX9-Wnt cross-regulation. The gene discussed is SOX9; the disease is diabetes mellitus.